Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, John B Haanen, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Djura Piersma, Roos S van Rijn, Karijn P M Suijkerbuijk, Willeke A M Blokx, Bert-Jan J Ten Tije, Astrid A M van der Veldt, Art Vreugdenhil, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

1 Article

1 results

2021

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis
van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., ten Tije, B. J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J. & van den Eertwegh, A. J. M., 30 Mar 2021, In: British Journal of Cancer. 124, 7, p. 1222-1230 9 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Research output

Search results

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis